RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
RECURSION PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.61+0.15 (+4.18%)
Close on Oct 19, 2026
- Market cap
- $1.92B
- P/E (TTM)
- –
- Dividend yield
- –
RECURSION PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating revenue | $7.30M | $6.30M | $35.35M | $4.98M | $19.10M | $14.82M | $4.51M | $26.08M | $14.40M | $13.49M | $10.62M | $10.10M | 95.2% | -61.8% |
| Grant revenue | $367.00K | $171.00K | $187.00K | $192.00K | $120.00K | -$73.00K | $35.00K | $0 | $13.00K | $303.00K | $267.00K | $431.00K | 4.8% | +205.8% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | $16.95M | $1.11M | – | – | $3.08M | $26.08M | – | – | – | – | – | – |
| United Kingdom | – | – | $18.59M | $4.07M | – | – | $1.14M | $0 | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Recursion Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.